Clicky

Anixa Biosciences, Inc.(ANIX)

Description: Anixa, a cancer-focused biotechnology company, is harnessing the body's immune system in the fight against cancer. Anixa is developing both diagnostics and therapeutics to detect cancer early, when it is most curable, and to treat those afflicted once diagnosed. It is developing the CchekTM platform, a series of inexpensive non-invasive blood tests for the early detection of solid tumors, which is based on the body's immune response to the presence of a malignancy. It is also developing chimeric antigen receptor T-cell (CAR-T) based immuno-therapy drugs which genetically engineer a patient's own immune cells to fight cancer. Anixa also continually examines emerging technologies in complementary or related fields for further development and commercialization.


Keywords: Medicine Biotechnology Cancer Clinical Medicine Emerging Technologies Solid Tumors Immune System Cancer Treatment Gene Therapy Leukemia Blood Test Amines Chimeric Antigen Receptor Immune Response

Home Page: www.anixa.com

ANIX Technical Analysis

3150 Almaden Expressway
San Jose, CA 95118
United States
Phone: 408 708 9808


Officers

Name Title
Dr. Amit Kumar Ph.D. Chairman & CEO
Mr. Michael J. Catelani CPA, MBA Pres, COO, CFO & Corp. Sec.
Mr. John Roop Sr. VP of Engineering
Mr. Thomas Schlumpberger Ph.D. Exec. VP of Diagnostics
Dr. Pamela D. Garzone Ph.D. Chief Devel. Officer

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 4.3718
Price-to-Sales TTM: 156.9819
IPO Date: 1987-01-01
Fiscal Year End: October
Full Time Employees: 4
Back to stocks